# EDGAR Filing Document

**Accession Number:** 0001130166
**File Stem:** 0000000000-25-008068
**Filing Date:** 2025-7
**Character Count:** 4717
**Document Hash:** 54986b792b0dd769fff72b140eae0750
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-008068.hdr.sgml**: 20260702

**ACCESSION NUMBER**: 0000000000-25-008068

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250731

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Bio Green Med Solution, Inc.
- **CENTRAL INDEX KEY:** 0001130166
- **STANDARD INDUSTRIAL CLASSIFICATION:** WHOLESALE-DURABLE GOODS, NEC [5099]
- **ORGANIZATION NAME:** 07 Trade & Services
- **EIN:** 911766850
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 333-286754

**BUSINESS ADDRESS:**
- **STREET 1:** 200 CONNELL DRIVE
- **STREET 2:** SUITE 1500
- **CITY:** BERKELEY HEIGHTS
- **STATE:** NJ
- **ZIP:** 07922
- **BUSINESS PHONE:** 908-517-7330

**MAIL ADDRESS:**
- **STREET 1:** 200 CONNELL DRIVE
- **STREET 2:** SUITE 1500
- **CITY:** BERKELEY HEIGHTS
- **STATE:** NJ
- **ZIP:** 07922

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Cyclacel Pharmaceuticals, Inc.
- **DATE OF NAME CHANGE:** 20060329

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** XCYTE THERAPIES INC
- **DATE OF NAME CHANGE:** 20001218
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001641172-25-020766

## Text-Extract

```

                                                            July 31, 2025

Datuk Dr. Doris Wong Sing Ee
Chief Executive Officer
Cyclacel Pharmaceuticals, Inc.
Level 10, Tower 11, Avenue 5, The Horizon
Bangsar South City, No. 8, Jalan Kerinchi
59200, Kuala Lumpur, Malaysia

       Re: Cyclacel Pharmaceuticals, Inc.
           Post-Effective Amendment No. 1 to Registration Statement on Form S-1
           Filed July 24, 2025
           File No. 333-286754
Dear Datuk Dr. Doris Wong Sing Ee:

       We have conducted a limited review of your registration statement and
have the
following comments.

        Please respond to this letter by amending your registration statement
and providing
the requested information. If you do not believe a comment applies to your
facts and
circumstances or do not believe an amendment is appropriate, please tell us why
in your
response.

       After reviewing any amendment to your registration statement and the
information
you provide in response to this letter, we may have additional comments.

Post-Effective Amendment No. 1 to Registration Statement on Form S-1 filed July
24, 2025
General

1.     We note that you have omitted substantially all of the disclosure
required by Part I of
       Form S-1 in this post-effective amendment to your registration statement
on Form S-
       1. Please amend to include all of the disclosures required by Part I.
Please note that
       such disclosure is necessary in order for your prospectus to be complete
pursuant to
       Section 10(a) of the Securities Act, whether or not there have been
changes to
       disclosure since the filing of the initial registration statement on
Form S-1.

2.     We note you entered into a share exchange agreement dated May 6, 2025,
with
       FITTERS Diversified Berhad, a Malaysian publicly listed company (
Fitters Parent   )
       and FITTERS Sdn. Bhd., a Malaysia private limited company and
wholly-owned
 July 31, 2025
Page 2

       subsidiary of Fitters Parent (   Fitters   ) whereby Fitters Parent will
exchange all of its
       ownership interest in Fitters representing 100% of all of the issued and
outstanding
       capital shares of Fitters, for 19.99 percent of all of the issued and
outstanding shares
       of your Common Stock. Please provide your analysis of whether you are
required to
       include financial statements of the business acquired under Rule 8-04 of
Regulation S-
       X and the related pro forma financial information required by Rule 8-05
of Regulation
       S-X. Refer to Part I, Item 11(e) of Form S-1.
        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence
of action by the staff.

       Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date of
the registration
statement.

       Please contact Jason Drory at 202-551-8342 or Chris Edwards at
202-551-6761 with
any other questions.

                                                            Sincerely,

                                                            Division of
Corporation Finance
                                                            Office of Life
Sciences
cc:   Debbie Klis

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._